Compare CCB & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | NNNN |
|---|---|---|
| Founded | 1997 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2018 | 2025 |
| Metric | CCB | NNNN |
|---|---|---|
| Price | $113.82 | $32.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $117.50 | N/A |
| AVG Volume (30 Days) | ★ 111.3K | 27.3K |
| Earning Date | 01-27-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.19 | N/A |
| EPS | ★ 3.17 | 0.06 |
| Revenue | ★ $343,667,000.00 | $8,185,146.00 |
| Revenue This Year | $85.02 | N/A |
| Revenue Next Year | $17.38 | N/A |
| P/E Ratio | ★ $36.31 | $518.11 |
| Revenue Growth | ★ 26.18 | 21.95 |
| 52 Week Low | $76.11 | $5.18 |
| 52 Week High | $119.58 | $55.65 |
| Indicator | CCB | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 56.49 |
| Support Level | $113.78 | $26.06 |
| Resistance Level | $119.58 | $44.73 |
| Average True Range (ATR) | 4.08 | 6.09 |
| MACD | 0.22 | -0.20 |
| Stochastic Oscillator | 54.36 | 50.51 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.